Miguel Lança
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Miguel Lança has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Raquel Guiomar
National Reference Laboratory for Influenza and Other Respiratory Viruses, National Institute of Health Doutor Ricardo Jorge, Portugal
3 shared publications Ana Paula Rodrigues
Department of Epidemiology, National Institute of Health Doutor Ricardo Jorge, Portugal
2 shared publicationsCamila Henriques
National Reference Laboratory for Influenza and Other Respiratory Viruses, National Institute of Health Doutor Ricardo Jorge, Portugal
2 shared publications- João Ferreira Guerra
Hospital de Sao Jose, Centro Hospitalar e Universitário de Lisboa Central, Lisbon, Portugal
2 shared publications - João Magalhães Pina
ULS São José, Portugal
2 shared publications - Luís Campos Pinheiro
Hospital de Sao Jose, Centro Hospitalar e Universitário de Lisboa Central, Lisbon, Portugal
2 shared publications
Latest Publications
- Open Access
- 6 June 2026
- Published by Elsevier in International Journal of Medical Microbiology
- Vol. 322, 151724
Advancing genomic surveillance of respiratory syncytial virus in Portugal through an adapted amplicon-based whole-genome sequencing workflow
- 6 June 2026
- Published by Elsevier in International Journal of Medical Microbiology
- Vol. 322, 151724
Open AccessAdvancing genomic surveillance of respiratory syncytial virus in Portugal through an adapted amplicon-based whole-genome sequencing workflow
- Open Access
- 30 November 2025
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 19 (12) , e70186
Nirsevimab Effectiveness Against RSV‐Related Hospitalisations in Children Under 24 Months: A Test‐Negative Case–Control Study in Portugal, 2024–2025
We assessed Nirsevimab effectiveness (NE) against respiratory syncytial virus (RSV)‐related hospitalisation in eligible children (< 2 years) using a test‐negative case–control design within the VigiRSV network (weeks 43/2024 to 16/2025). Among 341 participants (median age: 2 months; 91.2% without known chronic condition), 137 (40.2%) tested RSV‐positive. Adjusted NE against RSV‐related hospitalisation was 78.5% (95%CI: 59.3–89.0). Sensitivity analyses confirmed the robustness of the results. These findings support Nirsevimab's effect in a predominantly healthy infant population and contribute to informing public health decisions for RSV immunisation.
- 30 November 2025
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 19 (12) , e70186
Open AccessNirsevimab Effectiveness Against RSV‐Related Hospitalisations in Children Under 24 Months: A Test‐Negative Case–Control Study in Portugal, 2024–2025
We assessed Nirsevimab effectiveness (NE) against respiratory syncytial virus (RSV)‐related hospitalisation in eligible children (< 2 years) using a test‐negative case–control design within the VigiRSV network (weeks 43/2024 to 16/2025). Among 341 participants (median age: 2 months; 91.2% without known chronic condition), 137 (40.2%) tested RSV‐positive. Adjusted NE against RSV‐related hospitalisation was 78.5% (95%CI: 59.3–89.0). Sensitivity analyses confirmed the robustness of the results. These findings support Nirsevimab's effect in a predominantly healthy infant population and contribute to informing public health decisions for RSV immunisation.
- Open Access
- 13 October 2025
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 19 (10) , e70147
Genetic and Epidemiological Insights Into Respiratory Syncytial Virus Infections: A Comparative Study of Hospitalized Versus Community Cases in Portugal (2021–2023)
Background: Respiratory syncytial virus (RSV) is the leading cause of acute respiratory infection (ARI) in young children, but its genetic diversity requires ongoing surveillance. Methods: From 2021 to 2023, a total of 619 and 94 RSV‐positive samples from the National Respiratory Syncytial Virus Surveillance Network (VigiRSV) and the Sentinel Influenza and other respiratory viruses surveillance network (Sentinel ISN), respectively, were analysed. The RSV A and RSV B typing was assessed by a multiplex real‐time RT‐PCR. Sanger sequencing was performed on a subset of samples ( n = 495). Phylogenetic analysis was carried out on partial glycoprotein G sequences. Clinical and epidemiological data were compared through Pearson Chi‐Square tests. Results: RSV Subgroup A was more prevalent (53.5%, 85/159) in the 2021/2022 season, whereas in the 2022/2023 season, it was RSV Subgroup B (82.1%, 435/530) in both networks. RSV A strains in VigiRSV clustered mainly to A.D .1 (39.0%, 39/100), whereas in Sentinel ISN, they clustered in A.D .5 (30.0%, 3/10). RSV Type B clustered mainly to B.D.E.1 (96.6%, 372/385) in both networks. All lineages cocirculated during the study period and in both surveillance networks. Regional clusters were identified for both subgroups. Conclusions: This study provides new insights into RSV genetic variability in Portugal, namely, the cocirculation of lineages and intravariability among lineages within both subgroups during the study period and in all Portuguese regions. However, our study is based on partial sequencing of the G gene, and because of this limitation, our results should be considered with great caution.
- 13 October 2025
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 19 (10) , e70147
Open AccessGenetic and Epidemiological Insights Into Respiratory Syncytial Virus Infections: A Comparative Study of Hospitalized Versus Community Cases in Portugal (2021–2023)
Background: Respiratory syncytial virus (RSV) is the leading cause of acute respiratory infection (ARI) in young children, but its genetic diversity requires ongoing surveillance. Methods: From 2021 to 2023, a total of 619 and 94 RSV‐positive samples from the National Respiratory Syncytial Virus Surveillance Network (VigiRSV) and the Sentinel Influenza and other respiratory viruses surveillance network (Sentinel ISN), respectively, were analysed. The RSV A and RSV B typing was assessed by a multiplex real‐time RT‐PCR. Sanger sequencing was performed on a subset of samples ( n = 495). Phylogenetic analysis was carried out on partial glycoprotein G sequences. Clinical and epidemiological data were compared through Pearson Chi‐Square tests. Results: RSV Subgroup A was more prevalent (53.5%, 85/159) in the 2021/2022 season, whereas in the 2022/2023 season, it was RSV Subgroup B (82.1%, 435/530) in both networks. RSV A strains in VigiRSV clustered mainly to A.D .1 (39.0%, 39/100), whereas in Sentinel ISN, they clustered in A.D .5 (30.0%, 3/10). RSV Type B clustered mainly to B.D.E.1 (96.6%, 372/385) in both networks. All lineages cocirculated during the study period and in both surveillance networks. Regional clusters were identified for both subgroups. Conclusions: This study provides new insights into RSV genetic variability in Portugal, namely, the cocirculation of lineages and intravariability among lineages within both subgroups during the study period and in all Portuguese regions. However, our study is based on partial sequencing of the G gene, and because of this limitation, our results should be considered with great caution.
- Open Access
- 5 October 2024
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 4(84),p. 17-22
Renal carcinoma associated with end-stage kidney disease: A case series from a tertiary Portuguese hospital
End-stage kidney disease (ESKD) is associated with a higher incidence of renal cell carcinoma (RCC). Here we report a case series of 56 patients with ESKD who underwent radical nephrectomy for suspected renal masses at a tertiary hospital in Portugal from January 2017 to January 2024. Patient records were reviewed retrospectively to collect clinical, surgical, and pathological data. Among these patients, 12 had benign tumors, while 44 were diagnosed with malignant tumors, accounting for approximately 78.5% of the cohort. The histological analysis revealed the following distribution: clear cell RCC (20 cases, 45%), papillary RCC (11 cases, 25%), ACKD-associated RCC (6 cases, 14%), clear cell papillary RCC (4 cases, 9%), and chromophobe RCC (3 cases, 7%). Notably, the majority of patients (95.5%) had stage I malignant tumors, yet the prognosis for patients with ESKD was poorer compared to non-ESKD patients, with 7 patients succumbing during the follow-up period. This study underscores the complex relationship between ESKD and RCC, highlighting the challenges in diagnosis and management. Despite regular monitoring leading to early detection of tumors, the overall prognosis remains adversely affected by the compromised immune status and comorbid conditions prevalent in this population. The findings call for enhanced surveillance and personalized management strategies for RCC in patients with ESKD.
- 5 October 2024
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 4(84),p. 17-22
Open AccessRenal carcinoma associated with end-stage kidney disease: A case series from a tertiary Portuguese hospital
End-stage kidney disease (ESKD) is associated with a higher incidence of renal cell carcinoma (RCC). Here we report a case series of 56 patients with ESKD who underwent radical nephrectomy for suspected renal masses at a tertiary hospital in Portugal from January 2017 to January 2024. Patient records were reviewed retrospectively to collect clinical, surgical, and pathological data. Among these patients, 12 had benign tumors, while 44 were diagnosed with malignant tumors, accounting for approximately 78.5% of the cohort. The histological analysis revealed the following distribution: clear cell RCC (20 cases, 45%), papillary RCC (11 cases, 25%), ACKD-associated RCC (6 cases, 14%), clear cell papillary RCC (4 cases, 9%), and chromophobe RCC (3 cases, 7%). Notably, the majority of patients (95.5%) had stage I malignant tumors, yet the prognosis for patients with ESKD was poorer compared to non-ESKD patients, with 7 patients succumbing during the follow-up period. This study underscores the complex relationship between ESKD and RCC, highlighting the challenges in diagnosis and management. Despite regular monitoring leading to early detection of tumors, the overall prognosis remains adversely affected by the compromised immune status and comorbid conditions prevalent in this population. The findings call for enhanced surveillance and personalized management strategies for RCC in patients with ESKD.
- Open Access
- 5 August 2024
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 3(83),p. 3-7
Unraveling Zinner Syndrome: Insights from a distinct case
Zinner Syndrome (ZS) is a rare congenital malformation characterized by a triad of unilateral renal agenesis, ipsilateral seminal vesicle cyst, and ejaculatory duct obstruction. Typically discovered incidentally in the second to fourth decades of life, it presents with varied symptoms, including lower urinary tract symptoms, painful ejaculation, hemospermia, perineal pain, and infertility in 45% of cases. This article describes the case of ZS, highlighting the diagnostic and management approaches. Diagnosis relies on imaging techniques: ultrasound for initial assessment, computed tomography (CT) for detailed anatomical information and magnetic resonance imaging (MRI) as the gold standard for its superior soft-tissue contrast. Treatment depends on symptom severity and cyst size, ranging from conservative management for asymptomatic patients to surgical intervention for symptomatic cases. The primary surgical treatment involves the removal of the seminal vesicle cysts, which can effectively relieve symptoms such as pain, urinary discomfort, and ejaculatory dysfunction, thereby significantly enhancing the patient's quality of life. Minimally invasive laparoscopic or robotic surgery is preferred for its reduced morbidity and shorter recovery time. Infertility management includes surgical relief of ejaculatory duct obstruction and assisted reproductive technologies when necessary. Regular follow-up is essential for monitoring recurrences. Future research should focus on long-term outcomes and standardized management protocols to improve patient quality of life.
- 5 August 2024
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 3(83),p. 3-7
Open AccessUnraveling Zinner Syndrome: Insights from a distinct case
Zinner Syndrome (ZS) is a rare congenital malformation characterized by a triad of unilateral renal agenesis, ipsilateral seminal vesicle cyst, and ejaculatory duct obstruction. Typically discovered incidentally in the second to fourth decades of life, it presents with varied symptoms, including lower urinary tract symptoms, painful ejaculation, hemospermia, perineal pain, and infertility in 45% of cases. This article describes the case of ZS, highlighting the diagnostic and management approaches. Diagnosis relies on imaging techniques: ultrasound for initial assessment, computed tomography (CT) for detailed anatomical information and magnetic resonance imaging (MRI) as the gold standard for its superior soft-tissue contrast. Treatment depends on symptom severity and cyst size, ranging from conservative management for asymptomatic patients to surgical intervention for symptomatic cases. The primary surgical treatment involves the removal of the seminal vesicle cysts, which can effectively relieve symptoms such as pain, urinary discomfort, and ejaculatory dysfunction, thereby significantly enhancing the patient's quality of life. Minimally invasive laparoscopic or robotic surgery is preferred for its reduced morbidity and shorter recovery time. Infertility management includes surgical relief of ejaculatory duct obstruction and assisted reproductive technologies when necessary. Regular follow-up is essential for monitoring recurrences. Future research should focus on long-term outcomes and standardized management protocols to improve patient quality of life.